News & Updates

Treatment with vonoprazan leads to superior healing and maintenance of healing than the proton pump inhibitor (PPI) lansoprazole in patients with erosive oesophagitis, a new study has found.

Adjuvant chemotherapy with a modified dose of FOLFIRINOX (mFOLFIRINOX) was associated with significantly better survival outcomes, particularly disease-free survival (DFS) and overall survival (OS), compared with single-agent gemcitabine in patients with resected pancreatic ductal adenocarcinoma (PDAC), according to a 5-year analysis of the PRODIGE 24/Canadian Cancer Trials Group PA6* study.

Coffee lovers have more reasons to celebrate, with a recent study revealing health benefits from drinking coffee by reducing the risks of many medical conditions, including those in the cardiometabolic and gastrointestinal (GI) systems and those associated with alcohol use and oestrogen regulation.

New drug applications approved by US FDA as of 16-30 Sep 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Retreatment with infliximab (IFX) appears safe and effective in nearly a third of patients with Crohn’s disease (CD), independent of the reason for prior discontinuation, results of a study have shown.